价格

iPSC-NK

未知生产厂商

生成 AI 研报

专利

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

GENE-EDITED NATURAL KILLER CELLS
- EP 4251741 A1
  申请人: CRISPR THERAPEUTICS AG优先权: 2020
  EP
  US
  WO
  9 件公开
- US 20260250634 A1
  申请人: CRISPR THERAPEUTICS AG优先权: 2022
  US
  WO
  2 件公开
- US 20250241954 A1
  申请人: CRISPR THERAPEUTICS AG优先权: 2025
  US
CHIMERIC ANTIGEN RECEPTORS FOR NATURAL KILLER CELLS AND USES THEREOF IN IMMUNOTHERAPY
EP 4499681 A4申请人: SHORELINE BIOSCIENCES INC优先权: 2022
CN
EP
US
WO
4 件公开
CULTURE MEDIUM COMBINATION FOR INDUCING DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO CD34+ HEMATOPOIETIC STEM/PROGENITOR CELLS
US 20260015632 A1申请人: SHENZHEN CELL INSPIRE BIOTECHNOLOGY CO LTD优先权: 2023
CN
US
WO
3 件公开
A METHOD FOR INDUCING IPSC DIFFERENTIATION TO OBTAIN CD34+CELLS AND NK CELLS AND APPLICATION THEREOF
US 20250049847 A1申请人: ALLIFE MEDICINE BEIJING LTD优先权: 2022
CN
US
2 件公开
嵌合抗原受体、组合物以及方法
CN 113862292 B申请人: 明尼苏达大学董事会优先权: 2015
CN
2 件公开
Preparation method of ADCC function enhanced NK cell, NK cell and composition thereof
CN 116716342 A申请人: NANJING HELP REGENERATIVE MEDICAL TECH CO LTD优先权: 2022
CN
2 件公开
Production of chimeric antigen receptor modified t cells from stem cells and therapeutic uses thereof
CN 114945376 A申请人: HOPE CITY优先权: 2019
CN
Natural killer cells with enhanced activity
CN 116348121 A申请人: UNIV CALIFORNIA优先权: 2020
CN
Off-the-shelf iPSC-derived CAR-NK cells as monotherapy and in combination with antibodies
CN 117835993 A申请人: FATE THERAPAUETICS INC优先权: 2021
CN
一种针对实体瘤的通用性的IPS来源的CAR-NK细胞的制备方法
CN 115925974 B申请人: 再少年（北京）生物科技有限公司优先权: 2022
CN

药物

iPSC-NK

专利

GENE-EDITED NATURAL KILLER CELLS